Literature DB >> 11395570

Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.

W Yamamoto1, J Verweij, P de Bruijn, M J de Jonge, H Takano, M Nishiyama, M Kurihara, A Sparreboom.   

Abstract

Irinotecan (CPT-11) is a camptothecin analog with low (about 10--20%) and variable oral bioavailability in animal models. Here, Caco-2 cells were used to evaluate the transepithelial transport of CPT-11 and its metabolites. Caco-2 cells demonstrated significant expression of P-glycoprotein (P-gp), multidrug resistance-associated protein and canalicular multispecific organic anion transporter. Both the lactone and carboxylate forms of CPT-11 and SN-38 were actively transported across the cell monolayers, mainly by the apical-localized P-gp pump. Cellular permeability of CPT-11 at a concentration of 17 microM converted from active to passive-diffusional transport between the 2 and 6 h exposure time points. Antiproliferative effects of CPT-11 were related to permeability of the lactone form, whereas for SN-38 efficacy was dependent on lactone accumulation. Exposure of CPT-11 with cyclosporin A significantly enhanced its efficacy, whereas this was not observed with verapamil and R101933. In contrast, SN-38 efficacy decreased in the presence of P-gp inhibitors due to active transport toward the basolateral side, thereby reducing drug accumulation. Hence, multiple-active transport systems could be demonstrated to be responsible for not only accumulation profiles but also cytotoxic efficacy of CPT-11 and SN-38 in the intestinal Caco-2 cells. It is suggested that CPT-11 might act in a time-dependent manner and that SN-38-mediated cytotoxicity relates to (dose-dependent) lactone kinetics. The results detailed in this report could contribute toward the development of a clinically useful oral formulation of CPT-11 with improved absorption characteristics and suggest that cyclosporin A is a suitable agent for further research of this concept.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395570     DOI: 10.1097/00001813-200106000-00003

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  10 in total

1.  Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers.

Authors:  Rohit B Kolhatkar; Peter Swaan; Hamidreza Ghandehari
Journal:  Pharm Res       Date:  2008-04-26       Impact factor: 4.200

2.  P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.

Authors:  Michael Tagen; Yanli Zhuang; Fan Zhang; K Elaine Harstead; Jun Shen; Paula Schaiquevich; Charles H Fraga; John C Panetta; Christopher M Waters; Clinton F Stewart
Journal:  Drug Metab Lett       Date:  2010-12

Review 3.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

4.  G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.

Authors:  Deborah S Goldberg; Nirmalkumar Vijayalakshmi; Peter W Swaan; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2010-11-27       Impact factor: 9.776

5.  Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.

Authors:  Kazuhiro Yoshida; Kazuaki Tanabe; Hideaki Ueno; Kouji Ohta; Jun Hihara; Tetsuya Toge; Masahiko Nishiyama
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

6.  Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

Authors:  Kazuhiko Arimori; Noriaki Kuroki; Muneaki Hidaka; Tomomi Iwakiri; Keishi Yamsaki; Manabu Okumura; Hiroshige Ono; Norito Takamura; Masahiko Kikuchi; Masahiro Nakano
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

Review 7.  Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.

Authors:  Jörg T Hartmann; Hans-Peter Lipp
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 8.  Challenge for a better combination with basic evidence.

Authors:  Kazuhiro Yoshida; Kazuya Yamaguchi; Shinji Osada; Yoshihiro Kawaguchi; Takao Takahashi; Fumio Sakashita; Yoshihiro Tanaka
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

9.  Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.

Authors:  Marina Fittkau; Wieland Voigt; Hans-Jürgen Holzhausen; Hans-Joachim Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

10.  Liquid Chromatographic Method for Irinotecan Estimation: Screening of P-gp Modulators.

Authors:  M Tariq; L M Negi; Sushama Talegaonkar; F J Ahmad; Zeenat Iqbal; A M Khan
Journal:  Indian J Pharm Sci       Date:  2015 Jan-Feb       Impact factor: 0.975

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.